AcquisitionsClearwater's acquisition of Enfusion was transformational for the company, presenting a cross-sell opportunity and unlocking additional market potential by accessing Enfusion's hedge fund clients.
Financial PerformanceClearwater reported a strong end to 2024, with net dollar retention of 116% and ARR growth of 25% sending shares more than 15% higher after hours.
Revenue GrowthThe company re-iterated its long-term outlook with expectations of 20% revenue growth, 80% gross margins, and 40% adjusted EBITDA margins, even with slight near-term revenue growth dilution from the Enfusion acquisition.